News

Medigen´s T cell receptor technology highlighted in Nature Biotechnology

Medigene AG announced today that a scientific article on T cell receptors with optimal affinity to cancer antigens has been published in the current issue of the renowned journal "Nature Biotechnology" (doi:10.1038/nbt.3147 - published online 16 March 2015). The positive research results presented show an important scientific foundation for the clinical development of the TCR-based T cell therapy approach.

Prof. Thomas Blankenstein, Director of the Institute for Immunology at the Charité - Universitätsmedizin Berlin and working group leader at Max Delbrück Center for Molecular Medicine (MDC) Berlin: "We are very pleased that our intensive efforts of the past are now coming to fruition and open the door to provide new T cell-based immunotherapies for cancer patients."

Prof. Dolores J. Schendel, Chief Scientific Officer of Medigene AG: "This publication represents results from a long-standing alliance of teams in Berlin and Munich to develop tools and technologies to engineer patient lymphocytes to effectively attack their own tumours."

The article titled "Identification of T cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice" outlines the extensive pre-clinical developments regarding the identification of these specific T cell receptors.

http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3147.html 
(Cover (c) of nature.com)

The results have been generated in a research alliance between Prof. Thomas Blankenstein, Director of the Institute for Immunology at the Charité - Universitätsmedizin Berlin and working group leader at Max Delbrück Center for Molecular Medicine (MDC) Berlin in close cooperation with Prof. Dolores J. Schendel, now Chief Scientific Officer of Medigene AG. This alliance is supported since 2006 by the German Research Foundation of which Medigene Immunotherapies is a formal member.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit http://www.medigene.com


Newsletter

Subscribe

Archive